Cargando…

MBRS-57. IDENTIFICATION OF MYC-DEPENDENT THERAPEUTIC VULNERABILITIES FOR TARGETING GROUP 3 MEDULLOBLASTOMA

Group 3 medulloblastoma (MB(Group3)) is a highly aggressive tumour characterised by MYC amplification and elevated expression (17% of MB(Group3)). MYC amplification in MB(Group3) confers a dismal prognosis using standard therapies, and there is an urgent unmet need for novel therapeutic approaches....

Descripción completa

Detalles Bibliográficos
Autores principales:	Llargués-Sistac, Gemma, Lindsey, Janet, Swartz, Shanel, Selby, Matthew, Morcavallo, Alaide, Bailey, Simon, Chesler, Louis, Lord, Christopher J, Williamson, Daniel, Clifford, Steven C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Medulloblastoma (Research)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715234/ http://dx.doi.org/10.1093/neuonc/noaa222.562

Ejemplares similares

MBRS-33. TEMPORARY RESTORATION OF p53 ACTIVITY DURING FRACTIONATED RADIOTHERAPY IN A GROUP3 MEDULLOBLASTOMA GEMM REPRESENTS A POWERFUL TOOL FOR RADIOBIOLOGY STUDIES
por: Morcavallo, Alaide, et al.
Publicado: (2020)

MEDB-79. MYC-driven upregulation of thede novo serine and glycine pathway is a novel therapeutic target for Group 3 MYC-amplified Medulloblastoma
por: Adiamah, Magretta, et al.
Publicado: (2022)

MBRS-48. IDENTIFICATION OF NOVEL THERAPEUTIC APPROACHES FOR MYC-DRIVEN MEDULLOBLASTOMA
por: Taban, Kübra, et al.
Publicado: (2020)

MBRS-67. ROLE OF CYCLIN DEPENDENT KINASE-9 IN Myc-ENHANCED MEDULLOBLASTOMA
por: Madhavan, Krishna, et al.
Publicado: (2020)

MBRS-10. QUIESCENT SOX9-POSITIVE CELLS BEHIND MYC DRIVEN MEDULLOBLASTOMA RECURRENCE
por: Bolin, Sara, et al.
Publicado: (2020)

MEDB-36. Clinical and molecular heterogeneity withinMYC andMYCN amplified medulloblastoma
por: Schwalbe, Edward, et al.
Publicado: (2022)

MBRS-19. SYNERGISM OF HDAC AND PARP INHIBITORS IN MYC-DRIVEN GROUP 3 MEDULLOBLASTOMA CELLS
por: Vollmer, Johanna, et al.
Publicado: (2020)

MBRS-60. THE ACTIONABLE GENOMIC LANDSCAPE OF RELAPSED MEDULLOBLASTOMA IS DEFINED BY MAINTENANCE AND ACQUISITION OF DRIVER EVENTS
por: Richardson, Stacey, et al.
Publicado: (2020)

MBRS-04. MEDULLOBLASTOMA DETECTION BY BLOOD TEST
por: Yalon, Michal, et al.
Publicado: (2020)

MBRS-01. DISSECTING REGULATORS OF THE ABERRANT POST-TRANSCRIPTIONAL LANDSCAPE IN MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA
por: Kameda-Smith, Michelle, et al.
Publicado: (2020)

MBRS-64. STUDY OF ARGININE METHYL TRANSFERASES IN MEDULLOBLASTOMA
por: Cheng, Donghang, et al.
Publicado: (2020)

MBRS-22. SIGNIFICANCE OF RNF213 IN TUMORGENICITY OF MEDULLOBLASTOMA
por: Mineharu, Yohei, et al.
Publicado: (2020)

MBRS-44. TIME, PATTERN AND OUTCOME OF MEDULLOBLASTOMA RELAPSE ARE ASSOCIATED WITH TUMOUR BIOLOGY AT DIAGNOSIS AND UPFRONT THERAPY: A COHORT STUDY
por: Hill, Rebecca, et al.
Publicado: (2020)

MBRS-59. SINGLE-CELL WHOLE-GENOME SEQUENCING DISSECTS INTRA-TUMOURAL GENOMIC HETEROGENEITY AND CLONAL EVOLUTION IN CHILDHOOD MEDULLOBLASTOMA
por: Danilenko, Marina, et al.
Publicado: (2020)

MBRS-62. CURAXIN CBL0137 INHIBITS THE VIABILITY OF CANCEROUS CELLS IN PRE-CLINIC MODELS OF MYC-AMPLIFIED MEDULLOBLASTOMA
por: Wang, Jiajia, et al.
Publicado: (2020)

MBRS-53. CONTROL OF MEDULLOBLASTOMA VASCULATURE BY A REGULATOR OF NEUROGENESIS
por: Shaik, Shavali, et al.
Publicado: (2020)

MBRS-26. CDK7 MEDIATED TRANSCRIPTIONAL PROCESSIVITY OF DNA REPAIR NETWORKS REGULATES SENSITIVITY TO RADIATION IN MYC DRIVEN MEDULLOBLASTOMA
por: Veo, Bethany, et al.
Publicado: (2020)

MBRS-65. FBXW7 ACTS A TUMOR SUPPRESSOR IN MYC-DRIVEN MEDULLOBLASTOMA BY CONTROLLING A FEED-FORWARD REGULATORY LOOP OF PLK1 AND MYC
por: Wang, Dong, et al.
Publicado: (2020)

MBRS-70. FUNCTIONAL DEPENDENCY BETWEEN REST AND DNMT1 IN MEDULLOBLASTOMA
por: Maegawa, Shinji, et al.
Publicado: (2020)

MBRS-23. SIGNIFICANCE OF mi-R33 IN GENERATION AND PROGRESSION OF MEDULLOBLASTOMA
por: Matsui, Yasuzumi
Publicado: (2020)

MBRS-38. MOLECULAR CLASSIFICATION AND CLINICAL CHARACTERISTICS OF 236 MEDULLOBLASTOMAS IN JAPAN
por: Kanemura, Yonehiro, et al.
Publicado: (2020)

MBRS-17. EXAMINING THE ROLE OF LHX9 IN GROUP 3 MEDULLOBLASTOMA
por: Injac, Sarah, et al.
Publicado: (2020)

MBRS-71. ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN ATTENUATES DNA DAMAGE AND IS A THERAPEUTIC TARGET IN Myc-DRIVEN MEDULLOBLASTOMA
por: Abdel-Hafiz, Ahmed, et al.
Publicado: (2020)

MBRS-37. RECURRENT ACTIVATING MUTATIONS OF AKT GENES IN WNT-ACTIVATED MEDULLOBLASTOMAS
por: Masliah-Planchon, Julien, et al.
Publicado: (2020)

MBRS-63. THE ROLE OF THE SWI/SNF COMPLEX SUBUNIT SMARCD3 IN MEDULLOBLASTOMA
por: Poore, Brad, et al.
Publicado: (2020)

MBRS-45. TWIST1 AND ABCB1 ARE FUNCTIONAL DETERMINANTS OF METASTASIS IN MEDULLOBLASTOMA
por: Cardall, Alice, et al.
Publicado: (2020)

MBRS-32. TOPOISOMERASE II β INDUCES NEURONAL, BUT NOT GLIAL, DIFFERENTIATION IN MEDULLOBLASTOMA
por: Miyahara, Hiroaki, et al.
Publicado: (2020)

MBRS-02. BET BROMODOMAIN PROTEIN-KINASE INHIBITOR COMBINATIONS FOR THE TREATMENT OF MEDULLOBLASTOMA
por: Ayad, Nagi, et al.
Publicado: (2020)

MBRS-27. EXOSOMES CARRY DISTINCT miRNAs THAT DRIVE MEDULLOBLASTOMA PROGRESSION
por: Jackson, Hannah K, et al.
Publicado: (2020)

MBRS-69. METABOLITE PROFILING OF SHH MEDULLOBLASTOMA IDENTIFIES A SUBSET OF CHILDHOOD TUMOURS ENRICHED FOR HIGH-RISK MOLECULAR BIOMARKERS AND CLINICAL FEATURES
por: Bennett, Christopher, et al.
Publicado: (2020)

MBRS-42. YB-1 - A NOVEL THERAPEUTIC TARGET IN HIGH-RISK MEDULLOBLASTOMA?
por: Taylor, Louisa, et al.
Publicado: (2020)

MBRS-18. TUMOR SUPPRESSOR p53 DEFINES THE THERAPEUTIC RESPONSES IN TREATMENT OF MEDULLOBLASTOMA
por: Mohan, Avinash L, et al.
Publicado: (2020)

MBRS-47. RAPID MOLECULAR SUBGROUPING OF MEDULLOBLASTOMA BASED ON DNA METHYLATION BY NANOPORE SEQUENCING
por: Masliah-Planchon, Julien, et al.
Publicado: (2020)

MBRS-06. Gli3 INDUCES NEURONAL DIFFERENTIATION IN WNT- AND SHH- ACTIVATED MEDULLOBLASTOMA
por: Natsumeda, Manabu, et al.
Publicado: (2020)

MEDB-57.GNAS inactivation as a driver for sonic hedgehog-activated medulloblastoma
por: Goode, Erin, et al.
Publicado: (2022)

MBRS-31. COMBINING IRRADIATION AND ANTI-CD47 TO ENHANCE THE TREATMENT OF GROUP 3 MEDULLOBLASTOMA
por: Youssef, Osama, et al.
Publicado: (2020)

MBRS-28. EXOSOMES DRIVE MEDULLOBLASTOMA METASTASIS IN A MMP2 AND EMMPRIN DEPENDENT MANNER
por: Jackson, Hannah K, et al.
Publicado: (2020)

MBRS-13. MiR-1253 POTENTIATES CISPLATIN RESPONSE IN PEDIATRIC MEDULLOBLASTOMA BY REGULATING FERROPTOSIS
por: Kanchan, Ranjana K, et al.
Publicado: (2020)

MBRS-39. MAP4K4 CONTROLS PRO-INVASIVE SIGNALING IN MEDULLOBLASTOMA CELLS
por: Migliavacca, Jessica, et al.
Publicado: (2020)

MBRS-21. CLINICAL AGGRESSIVENESS OF TP53-WILD TYPE SONIC HEDGEHOG MEDULLOBLASTOMA WITH MYCN AMPLIFICATION
por: Mitani, Yuichi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qkeuq8eucdjq464tvpbh5hfo5v